AcouSort works since 2018 with Instrumentation laboratory (IL) on the integration of its technology into one of the in vitro diagnostic systems. AcouSort will now launch its third project linked to supporting this integration. The specific project will generate income of around 100 000 USD for AcouSort.
– We are very excited to start another project with IL. Since 2015, we have had a very successful collaboration, including a total of seven joint projects. We are happy and proud that HE recognizes us as leading experts in our field. Strategic collaborations with companies like IL are an important part of our long-term business strategy. We are now taking a further step towards realizing our ambition to manufacture and secure our technology as the preferred method for automated sample preparation for the life science industry, said AcouSort CEO Torsten Freltoft.
IL is a leading diagnostic company in the world with several products in the field of critical care and hemostasis. In 2018, AcouSort signed a license and distribution agreement for the implementation of AcouSort technology in the next generation of one of IL’s product families. The new project is a research and development project linked to this agreement and involves the study of a future modification of the product.
This information is information such as Acousort AB (publ) is required to publish in accordance with the EU Market Abuse Regulation. The information has been submitted, through the contact person below, for publication on October 5, 2021.
For more information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
Email: [email protected]
AcouSort AB (Company Registration Number 556824-1037) is an innovative technology company focused on the development of products and solutions for the integrated preparation of biological samples. Using sound waves, the company’s products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company’s products is acoustofluidics, where sound waves and microfluidics enable automated manipulation of samples in a range of application areas, from research into new biomarkers to the development of novel diagnostic systems for them. testing near the patient – this is called the Point of Care Systems (POC). The company’s marketing strategy is based on the proven business model of providing separation modules to manufacturers of diagnostic systems for integrated sample preparation and continuing to market the company’s research instruments. With the help of the company’s products and the development of point-of-care testing, new diagnostic systems and treatments are activated, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular illnesses.
(c) Decision 2021. All rights reserved., source Press Releases – English